[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Burkholderia pseudomallei Infections (Melioidosis) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 50 pages | ID: B197A98B2E59EN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Burkholderia pseudomallei Infections (Melioidosis) Drug pipeline report- 2020 is an annual R&D review of Burkholderia pseudomallei Infections (Melioidosis) pipeline candidates. The report presents the current status of all major Burkholderia pseudomallei Infections (Melioidosis) therapeutic compounds. Detailed insights into Burkholderia pseudomallei Infections (Melioidosis) pipeline development, current status, companies, drug profiles and Burkholderia pseudomallei Infections (Melioidosis) preclinical and clinical trials are included.

2020 Burkholderia pseudomallei Infections (Melioidosis) Pipeline Market Insights
Burkholderia pseudomallei Infections (Melioidosis) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Burkholderia pseudomallei Infections (Melioidosis) therapies, pipeline by phase and others are included.

Burkholderia pseudomallei Infections (Melioidosis) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Burkholderia pseudomallei Infections (Melioidosis) Therapeutic Drug candidates
Both active and inactive Burkholderia pseudomallei Infections (Melioidosis) pipeline drug candidates are included in the report

Burkholderia pseudomallei Infections (Melioidosis) Clinical Trials and preclinical Studies
Burkholderia pseudomallei Infections (Melioidosis) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Burkholderia pseudomallei Infections (Melioidosis) pipeline market developments
Burkholderia pseudomallei Infections (Melioidosis) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Burkholderia pseudomallei Infections (Melioidosis) pipeline companies in active development
The report analyzes Burkholderia pseudomallei Infections (Melioidosis) pipeline of the below companies-

Emergent BioSolutions Inc, Forge Therapeutics Inc, Grifols SA, MerLion Pharmaceuticals Pte Ltd, Soligenix Inc, Syntiron LLC, VenatoRx Pharmaceuticals

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
7 Companies investing in Burkholderia pseudomallei Infections (Melioidosis) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Burkholderia pseudomallei Infections (Melioidosis) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE MARKET INSIGHTS, 2020

1.1 Burkholderia pseudomallei Infections (Melioidosis) Disease Overview
1.2 Burkholderia pseudomallei Infections (Melioidosis) Drug Pipeline Snapshot, 2020
  1.2.1 Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs by Phase
  1.2.2 Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs by Company
  1.2.3 Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs by Mechanism of Action
  1.2.4 Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs by Route of Administration

2. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) COMPANY WISE PIPELINE DETAILS

Emergent BioSolutions Inc Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Forge Therapeutics Inc Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Grifols SA Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
MerLion Pharmaceuticals Pte Ltd Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Soligenix Inc Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Syntiron LLC Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
VenatoRx Pharmaceuticals Burkholderia pseudomallei Infections (Melioidosis) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications